News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • BofA warns a further ~3% S&P slide could prompt additional systematic selling.
  • EU reviews impact after U.S. export controls led Anthropic to disable access to its most advanced AI models for all users.
  • Mineralys, Upstream Bio, and Celldex reported trial data showing clinically meaningful effects and supporting planned regulatory actions.
  • Analyst trade ideas recommend buying Cogent for pre-approval optionality and Reddit for durable ad and AI-data revenue.
  • Strikes in Gaza killed at least six while mediators try to revive a U.S.-brokered truce, maintaining regional uncertainty.
  • G7 protesters in Geneva set a Tesla on fire and smashed bank windows, prompting heavy police presence and business security measures.

Latest Articles

Cuba's Daily Endurance: How Residents Keep Going Under Sanctions and a Fuel Blockade

Cuba's Daily Endurance: How Residents Keep Going Under Sanctions and a Fuel Blockade

Cubans across the island are coping with a deepening crisis after a U.S. campaign of tightened sanctions and a fuel blockade. Longstanding shortages and rationing have intensified, forcing creative local responses while fears of reprisals and a frayed public health system limit open protest. Despite severe hardship, the government remains firmly in…

Goldman Flags AI Risks as it Initiates Wolters Kluwer at Neutral

Goldman Flags AI Risks as it Initiates Wolters Kluwer at Neutral

Goldman Sachs began coverage of Wolters Kluwer with a Neutral rating and a €71 price target, describing the Dutch information services group as attractively valued but lacking near-term drivers for a material re-rating. The bank expects Wolters Kluwer to deliver steady EPS compound growth while flagging AI-related threats to key product pricing and…

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Tenaya Therapeutics announced encouraging interim data from its MyPEAK-1 Phase 1b/2 clinical trial evaluating TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM). The treatment showed consistent improvements in cardiac remodeling, reduction of left ventricular hypertrophy, symptom relief, and increased exercise capacity acro…

Destination XL Group, Inc. Reports First Quarter Financial Results

Destination XL Group, Inc. Reports First Quarter Financial Results

Destination XL Group, Inc. reported first quarter fiscal 2026 results with total sales declining 2.1% to $103.3 million and a net loss of $5.9 million compared to $1.9 million loss a year prior. The company is focused on strategic initiatives such as expanding its proprietary FiTMAP fit technology and leveraging AI to improve e-commerce discoverabi…

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Cocrystal Pharma Inc., a clinical-stage biotech company specializing in antiviral therapeutics, has named James Sapirstein as its new CEO effective immediately. Sapirstein brings extensive leadership experience in pharmaceutical development and commercialization, having led multiple product launches and held senior roles at major biopharma companie…

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

Ovid Therapeutics Inc. has appointed Dr. Anna Greka, a distinguished physician-scientist and biotech innovator, to its Board of Directors. Dr. Greka will chair Ovid's new Science and Technology Committee and contribute to advancing Ovid's pipeline of targeted therapies for neurological and neuropsychiatric disorders, including epilepsy and KCC2 act…

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Cabaletta Bio announced encouraging clinical data for its investigational autologous CAR T cell therapy, rese-cel, showing durable, immunomodulator-free responses in patients with autoimmune diseases including dermatomyositis, systemic sclerosis, and lupus. The data support advancement in registrational studies and highlight potential for precondit…

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

FibroBiologics has dosed the first patients in its Phase 1/2 clinical trial of CYWC628, a topical allogeneic fibroblast-spheroid cell therapy designed to treat diabetic foot ulcers (DFUs). The multicenter, randomized study in Australia aims to evaluate safety, tolerability, and efficacy by comparing CYWC628 plus standard of care (SoC) against SoC a…

SweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This Summer

SweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This Summer

SweetWater Brewing, the Southeast's leading craft beer brand and subsidiary of Tilray Brands (NASDAQ: TLRY), announced a citywide soccer celebration in Atlanta for summer 2026. Leveraging Atlanta hosting major international soccer matches, the program includes stadium activations, fan experiences, exclusive beer collaborations, and watch parties to…

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Kura Oncology reported encouraging Phase 1a clinical trial results demonstrating darlifarnib combined with adagrasib yields objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in colorectal cancer patients with KRAS mutations. The company is launching a flexible platform study to explore multiple darlifa…

Rocket Lab: Buying the Optionality on Neutron and a $2B Backlog

Rocket Lab: Buying the Optionality on Neutron and a $2B Backlog

Rocket Lab (RKLB) has posted rapid top-line growth and a backlog north of $2 billion while preparing the Neutron reusable rocket for a maiden flight by the end of 2026. At $123.31 the stock already prices a great deal of future optionality — this trade buys a defined-risk position ahead of key catalysts while acknowledging high valuation and execut…